Why the study?
Previous US studies on smoking and obesity interactions on IHD mortality had mixed findings and only evaluated multiplicative scales, whereas additive scales better inform public health interventions.
Does the combination of smoking and obesity have an additive interaction effect on ischemic heart disease mortality in adults?
Does the combination of smoking and obesity have an additive interaction effect on ischemic heart disease mortality in adults?
Smoking and obesity have a significant additive interaction on ischemic heart disease mortality, highlighting the compounded risk of these co-occurring modifiable risk factors.
May warrant joint smoking-obesity interventions; leaves open causal confirmation in diverse populations.
BACKGROUND: Smoking and obesity are important modifiable risk factors for ischemic heart disease (IHD), often clustering within the same individuals. Previous US studies showed mixed findings regarding their interaction effects on IHD mortality and only investigated the question on the multiplicative scale, while additive scale is better suited to inform public health interventions. METHODS: We linked the 1997-2018 National Health Interview Survey data to the 2019 National Death Index. A total of 579 503 adults aged 18 years and older were included. Mortality status or last presumed alive was assessed until 31 December 2019. We used Aalen's additive hazards models and calculated the relative excess risk due to interaction (RERI) from Cox proportional hazards models and Fine-Gray subdistribution models that accounted for competing risks to comprehensively evaluate the interaction effect of smoking with obesity on IHD mortality. RESULTS: During 10.4 years of follow-up on average, 13 231 IHD deaths occurred. The weighted mortality rate was 177.0 (95% CI: 172.3-181.7) per 100 000 person-years (PY). The combination of current everyday smoking and obesity was associated with 55.56 (95% CI: 30.37-80.74) additional deaths per 100 000 PY compared to the sum of their individual effects. This additive interaction was supported by multiplicative interactions (HR = 1.19, 1.03-1.39; HR = 1.40, 1.22-1.59) and large RERIs of 1.00 (0.59-1.40) and 0.85 (0.6-1.09) from the Cox and Fine-Gray models, respectively. CONCLUSIONS: Our findings highlight the importance of evaluating interactions on multiple scales, which reduces scale-dependence of the interaction effect and can translate better into public health strategies.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: